282 related articles for article (PubMed ID: 32805273)
21. Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.
Zschaeck S; Löck S; Hofheinz F; Zips D; Saksø Mortensen L; Zöphel K; Troost EGC; Boeke S; Saksø M; Mönnich D; Seidlitz A; Johansen J; Skripcak T; Gregoire V; Overgaard J; Baumann M; Krause M
Radiother Oncol; 2020 Aug; 149():189-196. PubMed ID: 32417350
[TBL] [Abstract][Full Text] [Related]
22. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
[TBL] [Abstract][Full Text] [Related]
23. A comparison of loco-regional relapse pattern in HPV positive vs negative oropharyngeal cancers following radiotherapy; relation to pretreatment FDG-PET and radiotherapy target volumes.
Håkansson K; Lindegaard AM; Bernsdorf M; Gothelf A; Kristensen CA; Specht L; Friborg J; Vogelius I
Acta Oncol; 2023 Sep; 62(9):1028-1035. PubMed ID: 37489000
[TBL] [Abstract][Full Text] [Related]
24. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.
Souvatzoglou M; Grosu AL; Röper B; Krause BJ; Beck R; Reischl G; Picchio M; Machulla HJ; Wester HJ; Piert M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1566-75. PubMed ID: 17447061
[TBL] [Abstract][Full Text] [Related]
25. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake.
Due AK; Vogelius IR; Aznar MC; Bentzen SM; Berthelsen AK; Korreman SS; Loft A; Kristensen CA; Specht L
Radiother Oncol; 2014 Jun; 111(3):360-5. PubMed ID: 24993331
[TBL] [Abstract][Full Text] [Related]
26. Correlation analysis of [
Di Perri D; Lee JA; Bol A; Hanin FX; Janssens G; Labar D; Robert A; Sterpin E; Geets X
Acta Oncol; 2017 Sep; 56(9):1181-1188. PubMed ID: 28537761
[TBL] [Abstract][Full Text] [Related]
27. The Effects of Human Papillomavirus Status and Treatment on the Positive Predictive Value of Post-radiotherapy
Zhou S; Chan C; Lau YC; Rulach R; Dyab H; Hendry F; Wilson C; Schipani S; Lamb C; Grose D; James A; Maxfield C; Dempsey MF; Paterson C
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e699-e707. PubMed ID: 37798198
[TBL] [Abstract][Full Text] [Related]
28. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia imaging with
Melsens E; De Vlieghere E; Descamps B; Vanhove C; Kersemans K; De Vos F; Goethals I; Brans B; De Wever O; Ceelen W; Pattyn P
Radiat Oncol; 2018 Mar; 13(1):39. PubMed ID: 29514673
[TBL] [Abstract][Full Text] [Related]
30. Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma.
Zegers CM; van Elmpt W; Hoebers FJ; Troost EG; Öllers MC; Mottaghy FM; Lambin P
Acta Oncol; 2015; 54(9):1378-84. PubMed ID: 26213313
[TBL] [Abstract][Full Text] [Related]
31. An Intensive 18F-Fludeoxyglucose-Positron Emission Tomography With Computed Tomography-Based Strategy of Follow-Up in Patients Treated for Head and Neck Squamous Cell Carcinoma Who Are Clinically Asymptomatic.
Leclère JC; Clément C; Le Pennec R; Maheo C; Gujral DM; Schick U; Le Gal G; Marianowski R; Salaun PY; Abgral R
JAMA Netw Open; 2023 Aug; 6(8):e2326654. PubMed ID: 37526935
[TBL] [Abstract][Full Text] [Related]
32. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
33. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
34. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
35. Use of Diffusion-Weighted Imaging and
Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
[TBL] [Abstract][Full Text] [Related]
36. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
[TBL] [Abstract][Full Text] [Related]
37. The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma.
Zhang I; Branstetter BF; Beswick DM; Maxwell JH; Gooding WE; Ferris RL
Arch Otolaryngol Head Neck Surg; 2011 Nov; 137(11):1106-11. PubMed ID: 22106234
[TBL] [Abstract][Full Text] [Related]
38. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
39. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
40. Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.
Trinkaus ME; Hicks RJ; Young RJ; Peters LJ; Solomon B; Bressel M; Corry J; Fisher R; Binns D; McArthur GA; Rischin D
J Med Imaging Radiat Oncol; 2014 Feb; 58(1):89-97. PubMed ID: 24529061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
